The market is up 8.4% in the last 7 days, with all sectors gaining ground, and over the past 12 months, it has risen by 5.9%, with earnings forecasted to grow by 13% annually. Penny stocks may be a throwback term, but the opportunities they represent are far from old news; these typically smaller or newer companies present an underappreciated chance for growth at lower price points. When combined with strong balance sheets and solid fundamentals, penny stocks can offer upside without many of the risks often associated with this corner of the market.

Top 10 Penny Stocks In The United States

Click here to see the full list of 788 stocks from our US Penny Stocks screener.

Below we spotlight a couple of our favorites from our exclusive screener.

Ardelyx

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Ardelyx, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for unmet medical needs in the United States and internationally, with a market cap of approximately $1.09 billion.

Operations: The company's revenue is derived entirely from the development and commercialization of biopharmaceutical products, totaling $333.62 million.

Market Cap: $1.09B

Ardelyx, Inc., a biopharmaceutical company, has shown significant revenue growth, reaching US$333.62 million for 2024 compared to US$124.46 million the previous year, while reducing its net loss from US$66.07 million to US$39.14 million. Despite being unprofitable with a negative return on equity of -22.58%, Ardelyx maintains a strong cash position exceeding its total debt and covers both short and long-term liabilities with assets of $356.5M and $184.6M respectively. Recent product advancements include the approval of XPHOZAH in China and ongoing clinical presentations in the U.S., enhancing its market potential internationally.

• Click here to discover the nuances of Ardelyx with our detailed analytical financial health report.
• Evaluate Ardelyx's prospects by accessing our earnings growth report.

Autolus Therapeutics

Simply Wall St Financial Health Rating: ★★★★☆☆

Overview: Autolus Therapeutics plc is a clinical-stage biopharmaceutical company focused on developing T cell therapies for cancer and autoimmune diseases, with a market cap of $356.61 million.

Operations: Autolus Therapeutics generates revenue primarily from developing and commercializing CAR-T therapies, amounting to $10.12 million.

Market Cap: $356.61M

Autolus Therapeutics, a clinical-stage biopharmaceutical company, reported revenue of US$10.12 million for 2024, up from US$1.7 million the previous year, though it remains unprofitable with a net loss of US$220.66 million. The company has more cash than debt and sufficient short-term assets to cover liabilities, but its debt-to-equity ratio has increased significantly over five years. Despite high volatility in share price and negative return on equity (-51.64%), Autolus forecasts revenue growth of 48% annually. Recent executive changes include Rob Dolski's appointment as principal accounting officer following Andrew Mercieca's resignation notice effective August 2025.

• Unlock comprehensive insights into our analysis of Autolus Therapeutics stock in this financial health report.
• Explore Autolus Therapeutics' analyst forecasts in our growth report.

Planet Labs PBC

Simply Wall St Financial Health Rating: ★★★★★★

Overview: Planet Labs PBC designs, constructs, and launches satellite constellations to provide high cadence geospatial data via an online platform globally, with a market cap of approximately $949.07 million.

Operations: The company generates revenue primarily from its data processing segment, which amounts to $244.35 million.

Market Cap: $949.07M

Planet Labs PBC, with a market cap of around US$949.07 million, is leveraging its high-frequency satellite data to secure significant multi-year contracts, such as those with onX and the European Space Agency. Despite being unprofitable with a net loss of US$123.2 million for 2024, the company reported revenue of US$244.35 million and maintains a robust cash position exceeding short-term liabilities by over US$160 million. Recent collaborations aim to enhance capabilities in sectors like agriculture and environmental monitoring, while strategic partnerships are expected to support sustainable growth within the thriving geospatial data industry.

• Navigate through the intricacies of Planet Labs PBC with our comprehensive balance sheet health report here.
• Gain insights into Planet Labs PBC's outlook and expected performance with our report on the company's earnings estimates.

Taking Advantage

• Reveal the 788 hidden gems among our US Penny Stocks screener with a single click here.
• Contemplating Other Strategies? The end of cancer? These 23 emerging AI stocks are developing tech that will allow early idenification of life changing disesaes like cancer and Alzheimer's.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Companies discussed in this article include NasdaqGM:ARDX NasdaqGS:AUTL and NYSE:PL.

This article was originally published by Simply Wall St.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com